Company Spotlight

Cytovance Biologics

800 Research Pkwy., Suite 200
Oklahoma City, OK 73104
United States
View Profile

Alcami

4620 Creekstone Drive
Durham, NC 27703
United States
View Profile

Aphena Pharma Solutions, Inc.

1920 Fisk Road
Cookeville, TN 38506
United States
View Profile


Contract Service Directory


Hovione





Company Headquarters

Estrada Paço do Lumiar
Edificio R Campus do Lumiar
Lisboa, Lisboa Portugal

Company Description

Hovione has over 57 years of experience as a CDMO and is currently a fully integrated supplier offering from drug substance to drug product intermediate to drug product. With four FDA inspected sites in the U.S., China, Ireland, and Portugal, and development laboratories in Lisbon and New Jersey, the company provides branded pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including support highly potent compounds. For generic pharmaceutical customers the company offers niche off-patent API products. In the inhalation area, Hovione is the only independent company offering services comprising drug substance, drug product intermediate, formulation and devices for dry powder inhalation. We remain fully committed to solving complex problems and delivering solutions that are highly valued by our customers. We are a company with a culture based on innovation, quality and delivery.

Contract Service Directory

    Related Content

    • Breaking News | Drug Development | Trials & Filings
      SK Bio Gains FDA Approval for XCOPRI

      SK Bio Gains FDA Approval for XCOPRI

      Marks the first time a Korean company has independently brought a compound from discovery to U.S. FDA approval
      11.25.19

    • Biologics, Proteins, Vaccines | Biosimilars
      Biopharma Over 20 Years

      Biopharma Over 20 Years

      A look at the key trends that have impacted the biopharma industry over the years.
      K. John Morrow, Jr. and Eric S. Langer, BioPlan Associates 11.20.19

    • Aseptic Processing | Breaking News | cGMP Manufacture | Facilities | Fill/Finish | Industry News
      Particle Sciences Becomes Lubrizol Life Science Health

      Particle Sciences Becomes Lubrizol Life Science Health

      Expands commercial-scale capabilities for drug product mfg; opens new 5,000 sq. ft. commercial mfg. facility in Bethlehem, PA.
      11.15.19


    • Breaking News | Industry News
      CPhI’s 16th Pharma Awards Winners

      CPhI’s 16th Pharma Awards Winners

      Dr. Ge Li wins ‘CEO of the Year’ and John Chiminski a ‘Lifetime Achievement’ award.
      11.13.19

    • Breaking News | Industry News | Regulatory Affairs | Solid Dosage/Creams/Ointments
      Absorption Systems Awarded Contract by FDA

      Absorption Systems Awarded Contract by FDA

      To conduct in vitro testing of the effects of excipients on oral drug absorption.
      11.01.19

    • cGMP Manufacture | Drug Development
      Contract Pharma’s 20th Anniversary Series: CDMO Insight

      Contract Pharma’s 20th Anniversary Series: CDMO Insight

      JoyL Silva of Pfizer CentreOne discusses global market and regulatory changes driving drug development strategies and the evolution of CDMO services and ops.
      Kristin Brooks, Contract Pharma 11.01.19


    • Vetter provides greater flexibility in secondary packaging through collaborative work

      Vetter provides greater flexibility in secondary packaging through collaborative work

      The CDMO increasingly relies on close interaction of humans and machines

    • Keynote: FDA’s Continuous Manufacturing Journey: Past, Present and Future

      Tuesday, November 5th, 1:30 PM - 2:30 PM   Keynote: FDA’s Continuous Manufacturing Journey: Past, Present and Future Location: 214 CD Manufacturing and Bioprocessing – Chemical…
      10.28.19

    • Breaking News | cGMP Manufacture | Clinical Trial Materials | Industry News
       Lonza’s Ibex Solutions to Support Genmab’s Clinical Portfolio

      Lonza’s Ibex Solutions to Support Genmab’s Clinical Portfolio

      New agreement will cover development and clinical manufacturing of drug substance and drug product for certain programs in Genmab’s pipeline
      10.16.19


    • APIs
      Better Drug Manufacturing Strategies: Custom APIs

      Better Drug Manufacturing Strategies: Custom APIs

      Today’s biopharma companies are turning to their contractors for long-term collaboration and much higher levels of support.
      Tom Wilson, VP, Global Contract Manufacturing Leader, Pfizer CentreOne 10.15.19

    • Breaking News | Clinical Trials | Industry News | Solid Dosage/Creams/Ointments
      Hovione Reports Successful End-of-Phase 2 Meeting With the FDA

      Hovione Reports Successful End-of-Phase 2 Meeting With the FDA

      Outlines Phase 3 program for Minocycline Topical Gel
      09.23.19

    • Breaking News | cGMP Manufacture | Collaborations & Alliances | Industry News | Injectables
      Pii to Manufacture FDA-Approved Hormone Therapy Injection Drug Product

      Pii to Manufacture FDA-Approved Hormone Therapy Injection Drug Product

      ANDA holder Sagent will sell, market and distribute the drug product in the U.S.
      09.23.19


    • Regulatory Affairs
      Quality Metrics Feedback

      Quality Metrics Feedback

      A look at FDA’s Quality Metrics Initiative, a complicated issue for all of pharma stakeholders
      Gil Roth, President, Pharma & Biopharma Outsourcing Association 09.16.19

    • Breaking News | Clinical Trials | Industry News | Inspections | QA/QC
      FDA Extends CRADA with CluePoints

      FDA Extends CRADA with CluePoints

      Aims to further explore a data-driven approach to quality oversight in clinical trials
      09.11.19

    • cGMP Manufacture | Collaborations & Alliances
      NIIMBL, FDA to Advance Innovation in Bio Manufacturing

      NIIMBL, FDA to Advance Innovation in Bio Manufacturing

      CRADA enables FDA and NIIMBL to support investments in regulatory science research, and training needed to foster advanced manufacturing innovations
      08.01.19

    • Industry News | Process Development
      Cambrex Expands Process Development at Edinburgh Facility

      Cambrex Expands Process Development at Edinburgh Facility

      Doubles current footprint to 15,000 sq. ft., adding lab space to accommodate 40 more scientists
      07.30.19

    • Trials & Filings
      FDA Accepts RedHill Biopharma’s NDA for Talicia

      FDA Accepts RedHill Biopharma’s NDA for Talicia

      Commercial launch of H. pylori treatment is planned shortly following potential FDA approval
      07.16.19

    • Trials & Filings
      SunGen Pharma Receives Sixth ANDA Approval from FDA

      SunGen Pharma Receives Sixth ANDA Approval from FDA

      Methylprednisolone approved for treatment of arthritis, allergic reactions, and immune system disorders
      07.09.19

    • Trials & Filings
      Sierra’s Momelotinib Granted FDA Fast Track Designation

      Sierra’s Momelotinib Granted FDA Fast Track Designation

      Underscores potential for momelotinib to address unmet needs of patients with Intermediate/High-Risk myelofibrosis who have previously received a JAK inhibitor
      06.19.19

    • Risk-Based Monitoring

      Risk-Based Monitoring

      Leveraging intelligent analytics to realize the full value of RBx and compliance with ICH E6 (R2)
      Richard Davies, Vice President, Solution Expert, CluePoints 06.13.19

    • The Orphan Promise

      The Orphan Promise

      New policy on rare disease treatments likely soon
      S. Harachand, Contributing Editor 06.13.19